Search
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalpegcetacoplan], a novel inhibitor of C3. … [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Radium Ra 223 dichloride
go.drugbank.com/drugs/DB08913ApprovedInvestigationalAs a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. … The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 DichlorideAutologous cultured chondrocytes
go.drugbank.com/drugs/DB10997ApprovedInvestigationalThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnPenbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. … Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib]. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
International brands: Kalymin NGlycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1
go.drugbank.com/bio_entities/BE0020167EnzymeHumansGlycosyltransferase that generates the core 1 O-glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins (PubMed:11677243).
Synonyms: Core 1 beta3-Gal-T1, Core 1 O-glycan T-synthaseFenretinide
go.drugbank.com/drugs/DB05076InvestigationalA synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(4-hydroxyphenyl)all-trans retinamiderdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]